U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood

Patent 6911315 Issued on June 28, 2005. Estimated Expiration Date: Icon_subject January 10, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Differential erythrocyte counts
Patent #: 5321975
Issued on: 06/21/1994
Inventor: Levine, et al.

Apparatus for indirect fluorescent assay of blood samples
Patent #: 5342790
Issued on: 08/30/1994
Inventor: Levine, et al.

Indirect fluorescent assay of blood samples
Patent #: 5460979
Issued on: 10/24/1995
Inventor: Levine, et al.

Assay of blood or other biologic samples for target analytes
Patent #: 5635362
Issued on: 06/03/1997
Inventor: Levine, et al.

Assembly for detecting blood-borne parasites and measuring blood sample parameters in a centrifuged sample of blood
Patent #: 5723285
Issued on: 03/03/1998
Inventor: Levine, et al.

Assay of blood or other biologic samples for target analytes
Patent #: 5759794
Issued on: 06/02/1998
Inventor: Levine, et al.

Assay of blood or other biologic samples for target analytes
Patent #: 5776710
Issued on: 07/07/1998
Inventor: Levine, et al.

Method for analyzing blood samples
Patent #: 5830639
Issued on: 11/03/1998
Inventor: Levine, et al.

Assay of blood or other biologic samples for target analytes
Patent #: 5834217
Issued on: 11/10/1998
Inventor: Levine, et al.

Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood Patent #: 6197523
Issued on: 03/06/2001
Inventor: Rimm, et al.

Inventors

Application

No. 10042016 filed on 01/10/2002

US Classes:

435/7.22, Parasite or protozoa435/7.1, Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay435/7.23, Tumor cell or cancer cell435/7.24, Leukocyte (e.g., lymphocyte, granulocyte, monocyte, etc.)436/63, BIOLOGICAL CELLULAR MATERIAL TESTED436/64, CANCER436/523, Carrier is particulate and the particles are of intentionally different sizes or impregnated differently with the immunochemicals436/536, INVOLVING IMMUNE COMPLEX FORMED IN LIQUID PHASE436/538, Separation of immune complex from unbound antigen or antibody73/61.71, For measuring solid components (e.g., particles)435/4MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

Examiners

Primary: Chin, Christopher L.

Attorney, Agent or Firm

International Class

G01N033/53

Abstract

A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence of target cells which have expressed surface epitopes that indicate intracellular infection by various viruses or other infectious agents, and also cells which have expressed surface epitopes that indicate the presence of non-infectious medical conditions. The analysis involves the examination of cells in the blood sample for the presence or absence of particular surface epitopes while the blood sample is disposed in a centrifuged blood sampling container. The epitopic analysis for the presence or absence of infected cells, or cells which indicate the presence of non-infectious medical conditions relies on the detection of known target expressed epitopes. The target epitopes on the target cell types are epitopes which are also known to be absent on normal circulating cells in the blood. Fluorophores or other labels with distinct wavelength emissions are coupled with specific binding agents such as lectins, antibodies, aptamers, or the like, which are directed against the target expressed epitopes. The epitopic analyses may be performed in or near the expanded buffy coat layer in the centrifuged blood sample. The epitopic analysis may be performed under magnification either visually and/or photometrically. The blood sampling container is sized to hold between about 1 and about 20 ml, preferably about 10 ml of blood, and contains an insert that occupies about 90-98% of the volume of the container bore in the area of the container where the target cells will, if present, be detected. The insert forces the target cells in question to reside in an annular space in the container which is adjacent to the circumference of the container bore. The entire analysis can be performed in a relatively short period of time which is typically a matter of minutes to single digit hours.

PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?